Connexion
E-mail
Mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

Accueil Zonebourse  >  Actions  >  Swiss Exchange  >  BB Biotech AG    BION   CH0038389992

BB BIOTECH AG

(BION)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéCommuniquésPublications officiellesActualités du secteurAnalyses ZonebourseRecommandations des analystes

BB Biotech : publishes its interim report

share with twitter share with LinkedIn share with facebook
24/07/2020 | 07:15

DGAP-Ad-hoc: BB BIOTECH AG / Mot-clé(s) : Rapport intermédiaire
BB Biotech AG publishes its interim report

24.07.2020 / 07:00 CET/CEST
Le contenu relève de la responsabilité de l'émetteur.


Media release of July 24, 2020

Interim report of BB Biotech AG as at June 30, 2020

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2020, which covers the results of its business activities for the first six months of 2020.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2020 amounted to CHF 422 mn (profit of CHF 554 mn in H1 2019). In the second quarter a profit of CHF 1'180 mn (loss of CHF 336 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at June 30, 2020 can be downloaded at www.bbbiotech.com.


For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch


www.bbbiotech.com

Company profile
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.


24.07.2020 CET/CEST Communiqué de presse transmis par Tensid EQS AG. www.eqs.com

L'éditeur est responsable pour le contenu de la nouvelle.


Langue : Français
Entreprise : BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Schweiz
Téléphone : +41 52 624 08 45
E-mail : info@bbbiotech.com
Site internet : www.bbbiotech.ch
ISIN : CH0038389992
Numéro valeur : A0NFN3
Bourses : Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; SIX
EQS News ID : 1100723

 
Fin du message DGAP News-Service

1100723  24.07.2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1100723&application_name=news&site_id=zonebourse

© EQS 2020
share with twitter share with LinkedIn share with facebook
Réagir à cet article
Réagir le premier
Publier
loader
Toute l'actualité sur BB BIOTECH AG
25/08Vaccin, Chine, Election, le décor est planté
25/08AVIS D'ANALYSTES DU JOUR : Aperam, ArgenX, Barco, Galapagos, Melexis, Esker, Soi..
28/07AVIS D'ANALYSTES DU JOUR : Daimler, Esker, Faurecia, Getinge, Lonza, LVMH, Miche..
24/07Bourse Zurich: la prudence de retour pour la dernière séance de la semaine
AW
24/07Bourse Zurich: pas de répit à l'approche de la mi-journée
AW
24/07Principales informations avant-Bourse
AW
24/07BB Biotech renoue avec les bénéfices au deuxième trimestre
AW
24/07BB BIOTECH : publishes its interim report
EQ
24/07Événements importants des semaines 30 et 31 du 24.07.2020 au 01.08.2020
AW
24/07Prévisions du jour vendredi 24 juillet
AW
Plus d'actualités
Recommandations des analystes sur BB BIOTECH AG
Plus de recommandations
Données financières
CA 2020 251 M 273 M 233 M
Résultat net 2020 321 M 349 M 298 M
Dette nette 2020 67,0 M 72,9 M 62,3 M
PER 2020 18,0x
Rendement 2020 4,54%
Capitalisation 3 756 M 4 098 M 3 490 M
VE / CA 2020 15,2x
VE / CA 2021 7 069x
Nbr Employés -
Flottant 97,2%
Graphique BB BIOTECH AG
Durée : Période :
BB Biotech AG : Graphique analyse technique BB Biotech AG | BION | CH0038389992 | Zone bourse
Tendances analyse technique BB BIOTECH AG
Court TermeMoyen TermeLong Terme
TendancesNeutreHaussièreHaussière
Evolution du Compte de Résultat
Consensus
Vente
Achat
Recommandation moyenne ACCUMULER
Nombre d'Analystes 4
Objectif de cours Moyen 72,67 CHF
Dernier Cours de Cloture 67,80 CHF
Ecart / Objectif Haut 22,4%
Ecart / Objectif Moyen 7,18%
Ecart / Objectif Bas -1,18%
Révisions de BNA
Dirigeants
Nom Titre
Erich Hunziker Chairman-Supervisory Board
Michael Hutter Head-Finance & Compliance
Clive A. Meanwell Vice Chairman-Supervisory Board
Klaus Strein Member-Supervisory Board
Thomas von Planta Member-Supervisory Board
Secteur et Concurrence
Var. 1janvCapitalisation (M$)
BB BIOTECH AG2.34%4 098
LONZA GROUP61.95%46 359
CELLTRION, INC.48.07%31 911
SEATTLE GENETICS, INC.56.51%31 116
IQVIA HOLDINGS INC.-0.28%29 471
MODERNA, INC.254.09%27 329